Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans von Ulrichts, Peter, Guglietta, Antonio, Dreier, Torsten, van Bragt, Tonke, Hanssens, Valérie, Hofman, Erik, Vankerckhoven, Bernhardt, Verheesen, Peter, Ongenae, Nicolas, Lykhopiy, Valentina, Enriquez, F Javier, Cho, JunHaeng, Ober, Raimund J, Ward, E Sally, de Haard, Hans, Leupin, Nicolas

Volltext

Recurrent urinary tract infections in women: risk factors, etiology, pathogenesis and prophylaxis von Guglietta, Antonio

Volltext

Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis von Howard, Jr, James F, Bril, Vera, Vu, Tuan, Karam, Chafic, Peric, Stojan, De Bleecker, Jan L, Murai, Hiroyuki, Meisel, Andreas, Beydoun, Said R, Pasnoor, Mamatha, Guglietta, Antonio, Van Hoorick, Benjamin, Steeland, Sophie, T'joen, Caroline, Utsugisawa, Kimiaki, Verschuuren, Jan, Mantegazza, Renato

Volltext

Drug Treatment of Sleep Disorders von Guglietta, Antonio

Volltext

Infrared Thermography Images Acquisition for a Technical Perspective in Screening and Diagnostic Processes: Protocol Standardized Acquisition von Politi, Stefano, Aloisi, Jr, Anna, Bartoli, Vittorio, Guglietta, Antonio, Magnifica, Fabrizio

Volltext

The Fixed-dose Combination Drug for Secondary Cardiovascular Prevention project: Improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose c... von Sanz, Ginés, MD, PhD, Fuster, Valentin, MD, PhD, Guzmán, Luis, MD, Guglietta, Antonio, MD, PhD, Arnáiz, Joan Albert, MD, PhD, Martínez, Felipe, MD, Sarria, Antonio, MD, PhD, Roncaglioni, Maria Carla, Biol Sci Dr, Taubert, Kathryn, PhD

Volltext

Thermodynamic concepts in the study of microbial populations: age structure in Plasmodium falciparum infected red blood cells von Ferrer, Jordi, Prats, Clara, López, Daniel, Vidal-Mas, Jaume, Gargallo-Viola, Domingo, Guglietta, Antonio, Giró, Antoni

Volltext

The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy von Epstein, Joel B., Gorsky, Meir, Guglietta, Antonio, Le, Nhu, Sonis, Stephen T.

Volltext

Issues to consider in the pharmaceutical development of a cardiovascular polypill von Guglietta, Antonio, Guerrero, Marta

Volltext

Long-term Safety and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study von Howard, James, Bril, Vera, Vu, Tuan, Karam, Chafic, Peric, Stojan, De Bleecker, Jan, Murai, Hiroyuki, Meisel, Andreas, Beydoun, Said, Pasnoor, Mamatha, Guglietta, Antonio, Ulrichts, Peter, T'joen, Caroline, Brauer, Edward, Utsugisawa, Kimiaki, Verschuuren, Jan, Mantegazza, Renato

Volltext

Efficacy, Safety, and Tolerability of Efgartigimod in Patients With Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study (4520) von Howard, James, Bril, Vera, Vu, Tuan, Karam, Chafic, Peric, Stojan, Murai, Hiroyuki, Guglietta, Antonio, Ulrichts, Peter, Vangeneugden, Tony, Utsugisawa, Kimiaki, Verschuuren, Jan, Mantegazza, Renato

Volltext

Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants von Jing, Shan, Zhang, Yu, Lin, Yang, Gu, Xiaowen, Liu, Jing, Guglietta, Antonio, Noukens, Jan, Van Bragt, Tonke, Wang, Lina, Chen, Jiajia, Reinhart, Harald, Pu, Xia

Volltext

Long-term Safety, Tolerability, and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study (S25.004) von Howard, James, Bril, Vera, Vu, Tuan, Karam, Chafic, Peric, Stojan, De Bleecker, Jan, Murai, Hiroyuki, Meisel, Andreas, Beydoun, Said, Pasnoor, Mamatha, Guglietta, Antonio, Ulrichts, Peter, T’joen, Caroline, Utsugisawa, Kimiaki, Verschuuren, Jan, Mantegazza, Renato

Volltext

Synthesis, Structure−Activity Relationships, and in Vivo Evaluations of Substituted Di-tert-butylphenols as a Novel Class of Potent, Selective, and Orally Active Cyclooxygenase-2 I... von Song, Yuntao, Connor, David T, Doubleday, Robert, Sorenson, Roderick J, Sercel, Anthony D, Unangst, Paul C, Roth, Bruce D, Gilbertsen, Richard B, Chan, Kam, Schrier, Denis J, Guglietta, Antonio, Bornemeier, Dirk A, Dyer, Richard D

Volltext

Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants: Efgartigimod in Healthy Chinese Parti... von Jing, Shan, Zhang, Yu, Lin, Yang, Gu, Xiaowen, Liu, Jing, Guglietta, Antonio, Noukens, Jan, Van Bragt, Tonke, Wang, Lina, Chen, Jiajia, Reinhart, Harald, Pu, Xia

Volltext

Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: Phase 3 adapt study results von Mantegazza, Renato, Bril, Vera, Vu, Tuan, Karam, Chafic, Peric, Stojan, Margania, Temur, Murai, Hiroyuki, Bilinska, Malgorzata, Shakarishvili, Roman, Smilowski, Marek, Guglietta, Antonio, Ulrichts, Peter, Vangeneugden, Tony, Utsugisawa, Kimiaki, Verschuuren, Jan, Howard, James

Volltext

Additional Analyses of the Phase 2 Efgartigimod Study in Myasthenia Gravis (4484) von Howard, James, Bril, Vera, Mantegazza, Renato, Beydoun, Said, De Rivera Garrido, Fancisco Javier, Piehl, Fredrik, Rottoli, Maria Rosa, Van Damme, Philip, Vu, Tuan, Ulrichts, Peter, Guglietta, Antonio, Beauchamp, Jon, de Haard, Hans, Verschuuren, Jan

Volltext

The Past, Present, and Future of Drug Development and Treatment in Sleep Disorders von Guglietta, Antonio

Volltext

Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+) : interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis von Howard, James F, Bril, Vera, Vu, Tuan, Karam, Chafic, Peric, Stojan, De Bleecker, Jan, Murai, Hiroyuki, Meisel, Andreas, Beydoun, Said R, Pasnoor, Mamatha, Guglietta, Antonio, Van Hoorick, Benjamin, Steeland, Sophie, T’joen, Caroline, Utsugisawa, Kimiaki, Verschuuren, Jan, Mantegazza, Renato, the ADAPT+ Study Group, [missing]

Volltext

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans von Ulrichts, Peter, Guglietta, Antonio, Dreier, Torsten, Bragt, Tonke van, Hanssens, Valérie, Hofman, Erik, Vankerckhoven, Bernhardt, Verheesen, Peter, Ongenae, Nicolas, Lykhopiy, Valentina, Enriquez, F Javier, Cho, JunHaeng, Ober, Raimund J, Ward, E Sally, de Haard, Hans, Leupin, Nicolas

Volltext